SCHEMBL14745654

SCHEMBL14745654

CCc1c(-c2ccc3c(ccn3C)c2)nc(OCc2ccccc2)c(C(=O)OC)c1OCc1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 2/20 0.41
LMNA P02545 1/20 0.40
HPGD P15428 1/20 0.40
MAPT P10636 6/20 0.38
TDP1 Q9NUW8 2/20 0.38
FAAH O00519 1/20 0.38
TP53 P04637 1/20 0.37
ALDH1A1 P00352 2/20 0.37
GAA P10253 1/20 0.37
PKM P14618 1/20 0.37
HSD11B1 P28845 1/20 0.37
PGK1 P00558 1/20 0.36
USP2 O75604 1/20 0.36
TSHR P16473 1/20 0.36
HSD17B10 Q99714 1/20 0.36
NOTUM Q6P988 1/20 0.36
PPARG P37231 1/20 0.36
CHRNA7 P36544 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14744837 0.84 CNR1 (0.44) CNR1LMNAHPGDMAPTTDP1
SCHEMBL14757928 0.84 CNR1 (0.40) CNR1HSD11B1PGK1CHRNA7
SCHEMBL14744834 0.84 FAAH (0.38) CNR1LMNAHPGDMAPTFAAH
SCHEMBL14745487 0.83 FAAH (0.38) CNR1LMNAHPGDMAPTFAAH
SCHEMBL14745159 0.82 IMPDH2 (0.42) CNR1LMNAHPGDMAPTTDP1
SCHEMBL14745735 0.80 CNR1 (0.40) CNR1LMNAHPGDMAPTTDP1
SCHEMBL14745761 0.79 PIK3CD (0.42) CNR1LMNAMAPTTSHRHSD17B10
SCHEMBL14745357 0.77 AS3MT (0.38) CNR1LMNAHPGDMAPTTDP1
SCHEMBL14745658 0.76 CNR1 (0.39) CNR1PPARG
SCHEMBL17597416 0.76 CTSA (0.38) CNR1LMNAHPGDMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9409905-B2 Antibacterial compounds and methods for use PTC THERAPEUTICS, INC. (US) 2016-08-09 US disclosed
US-9409905-B2 Antibacterial compounds and methods for use PTC THERAPEUTICS, INC. (US) 2016-08-09 US disclosed
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2015-02-05 US disclosed
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2015-02-05 US disclosed
EP-2750504-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC Therapeutics, Inc. (US) 2014-07-09 EP disclosed
WO-2013033258-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2013-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE MRPL21, SLC11A2, CLPP CNR1 4586/4885LMNA 2119/4885HPGD 1279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.